Claudia Ielo | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation	EUROPEAN JOURNAL OF HAEMATOLOGY	2024
Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia	JOURNAL OF CLINICAL MEDICINE	2024
Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety	EXPERT OPINION ON DRUG SAFETY	2024
Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors	EXPERT OPINION ON PHARMACOTHERAPY	2024
Understanding and overcoming resistance to tyrosine kinase inhibitors (TKIs) in Chronic myeloid leukemia (CML)	EXPERT REVIEW OF HEMATOLOGY	2024
Case Report: Infectious prophylaxis in hematological malignancies	FRONTIERS IN ONCOLOGY	2023
Case Report: Avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combination	FRONTIERS IN ONCOLOGY	2023
CCND2 mutations in atypical chronic myeloid leukemia: a report of two cases	LEUKEMIA & LYMPHOMA	2023
Systemic mastocytosis: 2023 update on diagnosis and management in adults	EXPERT OPINION ON EMERGING DRUGS	2023
One-month qRT-PCR BCR::ABL1 transcript threshold to predict early recurrence in chronic phase CML patients attempting first treatment free remission	EUROPEAN JOURNAL OF HAEMATOLOGY	2023
Validation of imatinib therapy failure score (IMTF) in chronic phase chronic myeloid leukemia in real life practice	LEUKEMIA & LYMPHOMA	2023
Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight	LEUKEMIA RESEARCH REPORTS	2023
Early death risk score in acute promyelocytic leukemia: A retrospective analysis from a monocentric cohort	EUROPEAN JOURNAL OF HAEMATOLOGY	2023
RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort	BLOOD ADVANCES	2022
Utility of procalcitonin and C-reactive protein as predictors of Gram-negative bacteremia in febrile hematological outpatients	SUPPORTIVE CARE IN CANCER	2022
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model	AMERICAN JOURNAL OF HEMATOLOGY	2022
SARS‐CoV‐2 vaccination in patients with paroxysmal nocturnal hemoglobinuria: an Italian multicenter survey	AMERICAN JOURNAL OF HEMATOLOGY	2022
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. a retrospective multicentric gimema study	HAEMATOLOGICA	2022
Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib	CANCERS	2021
Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?	BLOOD ADVANCES	2021